Dallas-based MicroTransponder is looking to treat neurological conditions with its aired Vagus Nerve Stimulation, which is designed to help patients with tinnitus as well as stroke victims. The ...

"We are pleased with CMS's decision to assign the Vivistim procedure to New Technology APC 1580, ensuring appropriate reimbursement for this groundbreaking therapy," said Richard Foust, ...

AUSTIN, Texas, Nov. 17, 2025 /PRNewswire/ -- MicroTransponder ®, Inc., a commercial-stage medical technology company and developer of the breakthrough Vivistim ® Paired VNS™ System for chronic stroke ...

AUSTIN, Texas, March 12, 2025 /PRNewswire/ — Announcing a $65 million Series F financing round, MicroTransponder ®, Inc., one of the fastest-growing stroke companies, is transforming the stroke ...

A year after its Vivistim system became the first vagus nerve stimulation implant approved by the FDA for use in stroke rehabilitation, MicroTransponder has raked in an oversubscribed funding round to ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min An Austin medical technology ...

US-based MicroTransponder has reported positive long-term results for stroke patients who received the company’s paired vagus nerve stimulation (VNS) therapy. The data, published in the medical ...

MicroTransponder’s Vivistim Paired VNS system is a chest implant that helps chronic ischemic stroke survivors regain motor function in their arms and hands by stimulating the nearby vagus nerve, the ...

AUSTIN, Texas, Jan. 31, 2023 /PRNewswire/ -- MicroTransponder®, Inc. announces that the Centers for Medicare and Medicaid Services (CMS) awarded the Vivistim® Paired VNS™ System transitional ...

AUSTIN, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- MicroTransponder, Inc., a commercial-stage medical device company today announced that it has changed its corporate name to Mobia Medical, Inc. ("Mobia ...